Skip to main content

Table 1 Patient demographics and baseline characteristics

From: The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

Characteristics Arm A Arm B Arm C All patients
  Motesanib Motesanib Motesanib  
  125 mg QD 75 mg BID 2 wk on/1 wk off 75 mg BID 5 d on/2 d off  
  n = 25 n = 12 n = 12 N = 49
Sex, n (%)     
 Women 10 (40) 6 (50) 5 (42) 21 (43)
 Men 15 (60) 6 (50) 7 (58) 28 (57)
Race, n (%)     
 White 22 (88) 11 (92) 11 (92) 44 (90)
 Black 2 (8) 0 (0) 0 (0) 2 (4)
 Hispanic 1 (4) 1 (8) 0 (0) 2 (4)
 Native Hawaiian or other Pacific Islander 0 (0) 0 (0) 1 (8) 1 (2)
Median age (range), y 59 (28–70) 52 (30–70) 59 (22–81) 58 (22–81)
Age group, n (%)     
 <65 y 18 (72) 10 (83) 9 (75) 37 (76)
 ≥65 y 7 (28) 2 (17) 3 (25) 12 (24)
 ≥75 y 0 (0) 0 (0) 1 (8) 1 (2)
Tumor type, n (%)     
 Thyroid 1 (4) 7 (58) 4 (33) 12 (24)
 Colon 3 (12) 0 (0) 1 (8) 4 (8)
 Non–small-cell lung 3 (12) 0 (0) 1 (8) 4 (8)
 Carcinoma of unknown origin 1 (4) 1 (8) 0 (0) 2 (4)
 Cervix 1 (4) 0 (0) 1 (8) 2 (4)
 Oral 1 (4) 0 (0) 1 (8) 2 (4)
 Ovarian 1 (4) 0 (0) 1 (8) 2 (4)
 Small-cell lung 0 (0) 2 (17) 0 (0) 2 (4)
 Soft tissue sarcoma 1 (4) 0 (0) 1 (8) 2 (4)
 Bile duct 1 (4) 0 (0) 0 (0) 1 (2)
Bone sarcoma 1 (4) 0 (0) 0 (0) 1 (2)
 Esophageal 1 (4) 0 (0) 0 (0) 1 (2)
 Kidney 1 (4) 0 (0) 0 (0) 1 (2)
 Liver 1 (4) 0 (0) 0 (0) 1 (2)
 Squamous cell carcinoma of head and neck 1 (4) 0 (0) 0 (0) 1 (2)
 Other 7 (28) 2 (17) 2 (17) 11 (22)
ECOG performance status, n (%)     
 0 14 (56) 8 (67) 9 (75) 31 (63)
 1 10 (40) 4 (33) 3 (25) 17 (35)
 2 1 (4) 0 (0) 0 (0) 1 (2)
Disease stage, n (%)     
 Stage III 1 (4) 0 (0) 0 (0) 1 (2)
 Stage IV 22 (88) 11 (92) 11 (92) 44 (90)
 Unknown 2 (8) 1 (8) 1 (8) 4 (8)
Number of sites of disease,* n (%)     
 0 1 (4) 0 (0) 1 (8) 2 (4)
 1 13 (52) 4 (33) 3 (25) 20 (41)
 2 10 (40) 5 (42) 6 (50) 21 (43)
 ≥3 1 (4) 3 (25) 2 (17) 6 (50)
Number of prior therapies,† n (%)     
 0 5 (20) 1 (8) 1 (8) 7 (14)
 1 5 (20) 1 (8) 2 (17) 8 (16)
 2 2 (8) 1 (8) 3 (25) 6 (12)
 ≥3 13 (52) 9 (75) 6 (50) 28 (57)
Alcohol use, n (%)     
 Never 1 (4) 5 (42) 4 (33) 10 (20)
 Former 5 (20) 1 (8) 2 (17) 8 (16)
 Current 18 (72) 5 (42) 5 (42) 28 (57)
 Missing 1 (4) 1 (8) 1 (8) 3 (6)
  1. BID = twice daily; ECOG = Eastern Cooperative Oncology Group; QD = once daily.
  2. *Sites of disease as assessed by investigator.
  3. †Prior therapies include all cancer therapies before study enrollment.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us

\